A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 498 participants.
Also called NCT01590771
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 498 participants
- Sponsor
- Registry
-
NCT01590771
-
- Main results
- Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01590771. Randomized; triple masking; primary purpose treatment. Start 2012-07-09 (actual); primary completion 2014-06-10 (actual). Results posted on 2015-05-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Gliclazide
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01590771- Content hash
5b524faa3bc0e09e2b50b15fe04c1b8dce76e51a068ac2ccc5e257da09210110